 Home > Medical News > Latest Medical News > Hengrui Medicine: HR17031 injection obtained the qualification of US FDA clinical trial

Hengrui Medicine: HR17031 injection obtained the qualification of US FDA clinical trial

 Last Update: 2021-08-10
 Source: Internet
 Author: User

Tags

cin 2 treatment

type type diabetes

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On July 1, Hengrui Pharmaceutical announced that the drug HR17031 injection has obtained the clinical trial qualification of the US FDA and is intended to be used for the treatment of type 2 diabetes

At present, two similar drugs have been approved by the FDA and the European Medicines Agency for the treatment of type 2 diabetes, namely Novo Nordisk’s Xultophy 100/3.

Up to now, Hengrui has invested approximately RMB 113.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.